-
Oppenheimer Has Positive Stance On Momenta Pharmaceuticals
Monday, July 11, 2011 - 7:50am | 96According to Oppenheimer, Momenta Pharmaceuticals (NASDAQ: MNTA) holds a positive stance. Oppenheimer said that on 7/11, the U.S. District Court will begin hearings regarding inequitable conduct claims in the TEVA vs. MYL/Sandoz Copaxone patent litigation. “However, it is possible for the Copaxone...
-
Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen; Deal Valued Up to EUR695M
Monday, July 11, 2011 - 7:34am | 62Micromet, Inc. (NASDAQ: MITI) announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to...
-
Deutsche Banks Reports Gilead Sciences 1Q To Miss
Monday, July 11, 2011 - 7:32am | 76According to Deutsche Bank, Gilead Sciences (NASDAQ: GILD) 2Q looks to miss. Deutsche Bank said that IMS script trends, after begin adjusted for pricing, suggests QoQ growth is not sufficient to meet US HIV Gilead rev consensus of $950M. “Our est adjusts for patients in 1Q11 given free drug in...
-
Vanda Pharmaceuticals Announces Exclusive License Agreement with Probiomed for Commercialization of Fanapt in Mexico
Monday, July 11, 2011 - 7:06am | 87Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt™ in Mexico. Under the terms of the agreement, Probiomed will seek...
-
Achillion Announces Initiation of Phase 1 Trial of ACH-2928 for the Treatment of Hepatitis C
Monday, July 11, 2011 - 7:05am | 182Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that it has begun dosing in a Phase 1 clinical trial of ACH-2928, a NS5A inhibitor, being developed for the treatment of chronic hepatitis C virus infection. The Phase 1 clinical study is a randomized, double-blind, placebo-controlled...
-
Nevada State Judge Denies Roche and Genentech's Motions to Dismiss PDL BioPharma's Complaint
Monday, July 11, 2011 - 7:03am | 133PDL BioPharma (NASDAQ: PDLI) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. (Roche) in PDL's lawsuit related to the 2003 settlement...
-
Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows
Sunday, July 10, 2011 - 6:15pm | 2231Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Friday's trading session (listed from highest total volume to lowest): 1) Melco Crown Entertainment (NASDAQ:...
-
Earnings Ahead 07-08-2011
Friday, July 8, 2011 - 5:26pm | 837Cusick's Corner Buyers showed up at the close, and I am holding the long deltas in the S&Ps and short deltas in the bonds over the weekend. The thought process is that next week we have earnings plus the anticipation for solid numbers that could potentially start to drive the market early. The...
-
Hottest and Coldest Sectors for Friday 7/8/11
Friday, July 8, 2011 - 5:24pm | 1918The S&P 500 lost 9.4 points, or 0.7%, in Friday's trading session, as a weaker-than-expected jobs report put an end to the recent market rally. The SPX is now 26.78 points lower than its 52-week high of 1370.58, which was set on May 2nd. The Sector breakdown for Friday's session is as follows...
-
Biotech/Pharma Investor Trading News Alert and Stock Chart for BioSante
Friday, July 8, 2011 - 2:32pm | 973Point Roberts, WA, LINCOLNSHIRE, Ill – July 8, 2011 – Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert and 5-day stock chart for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). The stock has reached as high as $3....
-
Calls Purchased on United Therapeutics
Friday, July 8, 2011 - 1:24pm | 111Shares of United Therapeutics (NASDAQ: UTHR) are lower on the session by 0.90%, currently trading at $55.22. The stock has been moving largely lower over the past three months and is currently trading below the 200-day moving average. Options traders are buying calls on the name today. A short...
-
Options Brief: Seattle Genetics
Friday, July 8, 2011 - 11:12am | 75Shares of Seattle Genetics (NASDAQ: SGEN) are lower on the session by 0.39%, trading at $20.55. Overall put volume is now running at 5.48x the daily average, with 0% of all puts traded being purchases on the offer. 1,748 contracts have traded on the session so far. Seattle Genetics, Inc. is a...
-
Top Performing Small Cap Stocks: July 7th (APAC, OCZ, BEBE, ACHN, HOTT)
Friday, July 8, 2011 - 11:00am | 349Small cap stock indices climbed higher on Thursday, thanks to news including an acquisition and better-than-expected results from retailers and a rising star tech company. But the holiday-shortened week is headed towards a rocky finish, as Friday morning's report on the June employment data was...
-
Top Performing Small Cap Stocks: July 7th (APAC, OCZ, BEBE, ACHN, HOTT)
Friday, July 8, 2011 - 11:00am | 349Small cap stock indices climbed higher on Thursday, thanks to news including an acquisition and better-than-expected results from retailers and a rising star tech company. But the holiday-shortened week is headed towards a rocky finish, as Friday morning's report on the June employment data was...
-
Piper Jaffray Rates Amylin Overweight
Friday, July 8, 2011 - 9:24am | 126According to Piper Jaffray, Amylin Pharmaceuticals (NASDAQ: AMLN) reported positive results from the thorough QT (tQT) study requested by the FDA in Bydureon's Complete Response Letter. Piper Jaffray said that the study met its primary endpoint showing no prolongation of the QTc interval at or...